Heparin-induced thrombocytopenia (HIT) is an immune-mediated response to heparin administration. HIT following cardiopulmonary bypass (CPB) procedures has not been clearly delineated in pediatric populations. By comprehensive retrieval of the pertinent literature published since 2000, 19 reports were collected with 33 pediatric patients recruited into this study. A female predominance was noted in this patient setting. HIT occurred after a mean heparin exposure of 2.8 times. Pediatric HIT following CPB showed different features from that with no CPB, by a longer span on postoperative day 1-16, and a significant negative correlation between the platelet count and time of occurrence of thrombocytopenia on postoperative day 1-8. The thrombus formation developed on postoperative day 13. Heparin discontinuation and use of coganulant substitute are the important treatments of choice. In HIT patients, continued heparin use may cause patient death or recurrence of HIT. HIT-related thrombosis was present in 69.6% of the patients with similar incidence rates of arterial and venous thrombosis; and the thrombosis could be managed by medical, surgical or device explant methods. The direct thrombin inhibitors lepirudin, argatroban and bivalirudin as well as the factor Xa inhibitor danaparoid can be used safely in most of the pediatric patients. The event-free survival rate of this patient setting was 69.7%.
INTRODUCTION
Heparin-induced thrombocytopenia (HIT) is an immunemediated response to heparin administration that promotes antibody-mediated platelet activation with a high risk of thrombotic complications. 1 HIT type I is a benign, with a transient drop in platelets by 40-50% with no more sequelae; whereas, HIT type II patients develop an immune-mediated thrombocytopenia, which leads to thromboembolic complications in >50% of the patients. 2 HIT is an intensely procoagulant disorder; and in adult cardiac surgery, patients carry both significant thrombotic morbidity (38-81%) and mortality (28%). 3 HIT is defined as a relative reduction of platelet count of 50% that develops within 5-14 days after heparin exposure. 4 In this article, HIT referred to HIT type II.
Unfractionated heparin (UFH) is immunogenic, and heparin-dependent antibodies may appear on postoperative day (POD) 5-10 in 25-50% of adult patients under-going a cardiac operation. A minority (1-3%) of the patients may have strongly activated platelets presenting with thrombocytopenia and excessive thrombin production, if UFH use sustains >1 week. 3 Thrombocytopenia is a major manifestation leading to the suspicion of HIT. 3 Detection of HIT-antibodies is necessary when there is a significant reduction of platelet counts, or, unexplained platelet count reduction to <100,000 platelets/L (100×10 9 /L), new thromboembolic complications during heparin use, skin reactions at the heparin injection site, or systemic reactions after heparin exposure. 5 HIT in children have been increasingly reported. 4 The prevalence of HIT was 0.058% and that of HIT with thrombosis was 0.046% in pediatric patients on UFH. 6 HIT seems to be uncommon in pediatric patients, and those receiving cardiac surgery under cardiopulmonary bypass (CPB) are at an increased risk. 7 The clinical features and management of HIT following procedures have not been clearly delineated in pediatric populations. In order to highlight the clinical aspects of HIT, following CPB and the alike procedures (including extracorporeal life support, extracorporeal membrane oxygenation, and ventricular assist device) in pediatric patients, a systematic review is made herewith. keywords used to identify articles included HIT, cardiac surgical procedures, cardiopulmonary bypass, extracorporeal life support, extracorporeal membrane oxygenation, ventricular assist device, heparin, unfractionated heparin, low molecular weight heparin, antiheparin platelet factor 4 antibody, particle gel immunoassay, and heparin-induced platelet activation assay, with a filter of pediatrics. The screening of the bibliographic references helped in completing the literature retrieval. Fifty-eight articles were found related to the topic and keywords in the literature search; and 19 articles, which met the inclusion and exclusion criteria during preliminary assessment, were included in the review. The exclusion criteria were unrelated to pediatric HIT following CPB (n=28), pediatric HIT developing before CPB (n=5), adult HIT following CPB (n=5), and HIT in pediatris with no CPB procedure (n=1).
The data independently extracted from each study were the study population, demographics, clinical diagnosis, surgical procedures, time of occurrences of HIT events, therapeutic strategies and effects, and patients' outcomes.
The measurement data were expressed in mean ± standard deviation and compared by independent sample t-test. The categorical variables were presented as frequency with percentage and were compared by Fisher exact test. The platelet count and time of occurrence of thrombocytopenia was also tested by linear correlation. p<0.05 was considered statistically significant.
RESULTS
A total of 19 reports were collected with 33 pediatric patients recruited into this study. 2, 7, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] Patients were at the age of 3.0 ±0.5 years (n=32). Patients' gender was not stated for 2 cases. For the remaining 30 cases, 18 (60%) were males and 12 (40%) were females ( 2 =2. 4, p=0.196 ). Patients' ages showed no difference between male and female patients (3.7 ±3.2 years vs. 1.6 ±2.5, t=1.861, p=0.075).
In 2 patients, the diagnosis was not given, but it was described as bridging to lung transplantation, 23 and for reoperation after previous mitral valve replacement, 24 respectively. In the remaining 31 patients, the most common diagnosis was hypoplastic left heart syndrome (Table I) . Fontan procedure was the most common operation performed before the development of HIT (Table II) .
Heparin exposure was described in 27 patients. In one patient it was described as several times, 11 and thus it was excluded from the statistical analysis. The heparin exposure of the remaining 26 patients were 2.8 ±1.8 times (n=25).
HIT and thrombosis: Postoperative platelet count was reported in 26 patients with 33 measurements with a mean of 50.1 ±29.1×10 9 /L (n=33), which occurred on POD 7.4 ±4.4. The correlation between the platelet count and time of occurrence of thrombocytopenia was not significant (r=-0.0224, p=0.454). It indicated that there were two stages of thrombocytopenia: the first was concentrated on POD 1-8 and the second appeared on HIT in pediatrics following CPB However, a significant negative correlation was found between the platelet count and time of occurrence of thrombo-cytopenia during POD 1-8 (r=0.5893, p=0.001).
In 22 (66.7%) patients, 25 positive diagnostic tests for confirmation of HIT were reported: a positive antiheparin platelet factor 4 antibody in 15 (60%) cases, 2, 9, [11] [12] [13] [15] [16] [17] [18] [19] [20] [22] [23] [24] [25] on POD 6.8 ±4.1 (n=5), 2,18,21,22 a positive particle gel immunoassay in 5 (20%) patients on POD 9.0 ±4.2 (n=4), and a positive heparin-induced platelet activation assay in 5 (20%) patients on POD 11.8 ±5.7 (n=4). 21, 22, 24 Of the patient setting, 10 (30.3%) patients did not have thrombosis, whereas 23 (69.7%) patients did ( 2 =10.2, p=0.003). 7, 9, 14, 19, 21, 24 The sites of thrombosis formation of the 23 patients were listed in Table III . Most occurred in the device circuit, followed by in the human vessels with more in the vein than in the arteries but lack of statistical significance [60% (6/10) vs. 40% (4/10),  2 =0.8, p=0.656). The formation time of 8 thromboses of 6 patients were on POD 13 ±7.5 (n=8). 12, 13, 16, 18, 21, 22 In 7/33 (21.2%) patients, one or more organ failure developed: renal failure in 3/7 (42.9%) patients, 11, 18 heart failure in 1/7 (14.3%) patient, 13 heart and renal failure in 2/7 (28.6%) patients, 2, 12 and multisystem organ failure in 1/7 (14.3%) patient. 22 Treatment: Discontinuation of heparin was described in 25 patients. In 1 (4%) patient, heparin was not stopped and the patient eventually died of HIT. 7 In the remaining 24 (96%) patients, heparin was discontinued after diagnosis of HIT. Heparin/UFH was used in 22 (91.7%) patients and low molecular weight heparin (LMWH) and heparin in 2 (8.3) patients ( 2 =33.3, p<0.001). 17, 21 Time of discontinuation of heparin was 7.4 ±4.3 days after the operation (n=21). The treatment of HIT lasted for 16.8 ±15.2 days (n=12). [12] [13] [14] 16, 17, [21] [22] [23] [24] A substitute anticoagulant was not used in 3 (9.1%) patients. 7, 22 In the remaining 30 (90.9%) patients, argatroban was the most commonly used substitute anticoagulant followed by bivalirudin (Table IV) . The administration of these substitute anticoagulants included bolus, continuous infusion, CPB priming, and catheterisation, etc. Statistical analyses showed that there were no significant differences between the commonly used substitute anticoagulants and heparin in terms of target activated partial thromboplastin time and activated clotting time.
Left ventricular assisted device or extracorporeal life support was used in four (12.1%) patients, 11, [16] [17] [18] and extracorporeal membrane oxygenation was instituted in five (15.6%) patients. 7, 13, 18, 21, 25 Outcomes: Twenty-three (69.7%) patients were eventfree survivors, 7, 9, 10, [12] [13] [14] [15] [16] [17] [20] [21] [22] 24, 25 one (3.0%) patient was HIT-recurrent, 19 and nine (27.3%) patients died. Of the deceased patients, seven (77.8%) died of HIT, 2, 7, 11, 18, 21, 22 and two (22.2%) died of non-HIT, 21, 23 with one of them died of sudden bradycardia. 21 In the recurrent patient, the platelet count decreased significantly following reoperation and second reoperation with the use of tirofiban and heparin. Anticoagulation with lepirudin was started on day 3 after second reoperation and coumadin was started on day 6. On day 10, the platelet count had recovered. 19 In HIT patients, continued heparin use may cause patient death, 7 or recurrence of HIT. 19 But in one patient, heparin use even after HIT caused no problem. 19 Treatment of HIT was not mentioned in 11 (33.3%) patients. In the remaining 22 (66.7%) patients, heparin discontinuation with the use of substitute anticoagulant was applied in 16 (72.7%) patients, 2, 9, 11, 12, [14] [15] [16] [19] [20] [21] 23, 25 heparin discontinuation in 4 (18.2%), 10, 13, 22 use of substitute anticoagulant (bivalirudin) in 1 (4.5%), 21 and multiple platelet transfusions in 1 (4.5%) patient. 17 In the above 16 patients, the substitute anticoagulants were bivalirudin (n=6), 9, 20, 21, 23 tirofiban with subsequent lepirudin, 19 lepirudin (n=3), 12, 15, 16 argatroban (n=4), 2, 14, 25 antiplatelet (n=1), 11 and fondaparinux (n=1). 7 In one of them, tirofiban failed to increase the activated partial thromboplastin time to the target value. 19 The treatment of thrombosis revealed a success in 11/16 (68.8%) patients and a failure in 5/16 (31.3%) patients ( 2 =4.50, p=0.076, Table V) . 
DISCUSSION
The clinical and diagnostic features of HIT type II in this pediatric population were similar to adults. 25 The incidence of HIT was documented to be 2.3-3.7% in pediatric patients where 1-3% were following cardiac operation with the use of UFH. 26 The median platelet nadir was 58 (range, 27-191) ×10 9 /L, and thrombosis occurred a median of 10 (range, 5-45) days after the start of heparin therapy. 27 Klenner et al. summarized literature information and proposed that the most frequent manifestation of HIT was platelet count reduction (58/69, 84.1%). 28 HIT was associated with thromboembolic complications in 48/69 (69.6%) patients.
Takemoto et al. reported that, in adults with HIT, 30-60% had thrombosis at the time of clinical diagnosis and venous events were more common than arterial. 29 Similarly, most thrombotic events reported in pediatric patients appeared to be venous rather than arterial; perhaps in part due to a decreased incidence of atherosclerosis in pediartrics. A clinical study on a large patient population revealed predominance of venous thrombosis (2.4:1), with pulmonary embolism in 40% of the patients. In contrast, post-cardiac surgical patients showed predominance of arterial thrombosis (1:8.5), and the prevalence of arterial thrombosis (limb artery thrombosis >thrombotic stroke >myocardial infarction) was opposed to that in the non-HIT patient population. The HIT-related thrombosis presented on the same day more common than before the day of platelet count reduction (59.8% vs. 33.5%). In adults, orthopedic / trauma surgery and the degree of platelet count reduction were the most important risk factors for thrombosis. 5 Schmugge et al. reported that the calculated incidence of pediatric HIT-associated thrombosis was 2.3%, at a similar prevalence with adults. 30 Schmugge et al. noted that, of their 14 patients with HIT-associated thrombosis, 9 (64.3%) were from the veins, 2 (14.3%) from the arteries, and 3 (21.4%) from both the artery and the vein. None of their patients died or required amputation. 30 In adults, the risk of developing HIT is influenced by the patient population (surgical >medical), the type of heparin (bovine >porcine, UFH >LMWH >fondaparinux), the dose (therapeutic >prophylactic >heparin flushes), the route of administration (intravenous >subcutaneous), the duration of administration (higher with 4 or more days), and patient gender (female >male). 26 The risk of children developing HIT was related to the extent of UFH exposure, and the most frequent HIT in children was due to prolonged UFH exposure or higher cumulative doses of UFH. 26 The contribution of the extracorporeal membrane oxygenation circuit to thrombocytopenia was noted. 25 Half children were antibody-positive after reexposure to UFH in reoperations, whereas only 1.3% developed clinical HIT. 31 This proportion was similar to that of adults undergoing cardiac surgery in which 27-50% of patients showed a positive platelet factor 4 antibody, and 1-2% developed clinical HIT. 26 Late thrombocytopenia was related to a combination of factors (operation severity, degree of hypothermia during CPB, prolonged use of UFH, and milrinone). 32 The clinical diagnosis of HIT is based on platelet count reduction by >50% from baseline within 4-14 days after heparin therapy; with or without thrombosis or bleeding; or positive heparin-dependent antibodies. 26 However, for some patients, the lowest platelet count can be within the normal range. Thus, a more accurate indicator of HIT is platelet count reduction of >50% from baseline. HIT should be suspected in pediatrics with normal platelet counts with thrombosis of unknown origin. Moreover, a positive platelet factor 4 antibody does not necessarily lead to the diagnosis of HIT, as this may occur transiently in 27-50% of the adult patients, and recover to normal after a median of 50 days. 33 If pediatric HIT is left untreated, 42% would show poor outcomes, whereas the prevalence of those with poor outcomes would decrease to 18% when a substitute anticoagulant is used. 25 Any time HIT is suspected, discontinuation of heparin should be strongly considered and confirmatory diagnostic testing should be performed. 29 Early recognition of HIT type II is vital because withdrawal of all forms of heparin is the first and most important aspect of therapy. 25 Clinical strategy now avoids heparin exposure for patients positive for antiheparin platelet factor 4 antibody who are potentially at risk of developing HIT. 33 The reported treatment regimens are very heterogeneous. 28 In the presence of thrombosis, anticoagulation for the thrombotic event is generally recommended as, at least 3 months for deep vein thrombosis, and 3-6 months for pulmonary embolism. 29 The direct thrombin inhibitors lepirudin, argatroban and bivalirudin as well as the factor Xa inhibitor danaparoid have been used with success for treatment of HIT in children. Both bivalirudin and argatroban have short half-lives and both have been studied for pediatric use. 29 Bivalirudin has been shown to be effective in cardiac surgery with and without CPB. 26 Argatroban is cleared hepatically, whereas bivalirudin is primarily proteolyzed in the plasma. 29 It is highly specific in its ability to irreversibly bind to both the catalytic and enzymatic sites of thrombin. But contraindications to lepirudin were found for anticoagulation on CPB in patients with renal and coagulation disorders. Lepirudin has a longer halflife than bivalirudin and argatroban, and is cleared renally, 29 and hemofiltration or hemodialysis should be performed in patients with renal dysfunctions. 33 Danaparoid treatment of pediatric HIT patients has been reported, but in adults, intraoperative clotting and postoperative bleeding often occurred. 26 Fondaparinux is an indirect inhibitor of Xa, and it has also been applied in pediatrics. 29 All agents, regardless of its metabolic pathway, displayed similar bleeding incidences, and none seemed to carry a greater risk. 26 Pediatric HIT is often associated with a hypercoagulable state, carrying the risk of thrombus formation. Except for venous thrombosis, arterial occlusions and stroke occurred. Limb amputation was necessary in 4% of pediatric patients with HIT, and 11.6% (8/69) died. Pouplard et al. stated that, if LMWH are used instead of UFH post-cardiac surgery in adults, the incidence of HIT would be reduced. 31 As in younger children, HIT seems to occur following cardiac operation, the postoperative use of LMWH should be further investigated. Substitution of UFH by LMWH whenever possible is most likely to be effective in decreasing the risk of HIT in pediatrics. 28 In HIT infants, pretreatment with epoprostenol sodium before heparin reexposure may offer a safe and effective anticoagulation for CPB. 34 A novel finding of this study was a two-staged occurrence of HIT following CPB procedures, on POD 1-8 and on POD 14-16. In the first stage, a significant negative correlation was found between the platelet count and time of occurrence of thrombocytopenia. UFH was more commonly used and caused more chances of HIT than LMWH. During the treatment of HIT, the adverse effect of the substitute anticoagulants was only seen in one patient, in whom lepirudin was used, but discontinued 4 hours later, due to lung and gut bleeding. 11 In another patient, tirofiban failed to increase the activated partial thromboplastin time to the target value. 19 There were three choices to treat HIT-related thrombosis: surgical, medical or device exchange. No significant differences were found in terms of the success rates between the three choices.
CONCLUSION
Pediatric HIT following CPB showed different features from that with no CPB, by a longer span on POD 1-16, and a significant negative correlation between the platelet count and time of occurrence of thrombocytopenia on POD 1-8. Heparin discontinuation and use of coganulant constitute are the important treatments of choice. In HIT patients, continued heparin use may cause patient death or recurrence of HIT. HIT-related thrombus could be managed by medical, surgical or device explant methods. The direct thrombin inhibitors lepirudin, argatroban and bivalirudin as well as the factor Xa inhibitor danaparoid can be used safely in most of the pediatric patients.
